Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
By Michael W. Fried, M. Shiffman, K. R. Reddy, Coleman Smith, G. Marinos, F. Gonçales, Dieter Häussinger, Moisés Diago, Giampiero Carosi, D. Dhumeaux and 4 more. New England Journal of Medicine, 2002
669 citations recorded by the source corpus.
Subfields: Hepatology, Radiology, Nuclear Medicine and Imaging, Rheumatology
View Paper: https://www.semanticscholar.org/paper/c26b6b3c828ccd24eec011467ab6e328919fda9a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
Citations in the corpus
- Effect of pegylation on pharmaceuticals (2003, background): “However, the proportions of patients with HCV genotype 1 who sustained virologic response were only 46 and 35%, respectivel”
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (2009, background): “Treating HCV infection with PEG-IFN-α/RBV produces a varied decrease in viral replication and clinical outcom”
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C (2009, background): “Large-scale studies on 48-week-long PEG-IFN-α/RBV treatment in the United States and Europe showed that 42–52% of patients with HCV genotype 1 achieved SV”
- Mechanism of action of interferon and ribavirin in treatment of hepatitis C (2005, background): “SVR rates range from 42p to 46p in patients with genotype 1, which accounts for ∼70p of cases in the US”
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018, neutral): “5 g/dl [39-47].”
- Antiviral agents active against influenza A viruses (2006, background): “So, extensive experience with this combination has been accumulate”